Nemaura\u00a0Pharma has been recognised for its excellence in innovation\u00a0by the European\u00a0Eurostars\u00a0program having successfully secured a \u00a30.25m grant award for its unique MAP (microarray-patch) platform technology.\u00a0The award was received in conjunction with a partner company in the Netherlands whereby the project aims to produce a mass scale manufacture process using a large area maskless fabrication approach.<\/p>\n\n\n\n
The EUREKA\u00a0Eurostars\u00a0grant is a funding program that supports research and development (R&D) projects undertaken by small and medium-sized enterprises (SMEs) in Europe. It is a joint initiative of EUREKA, a pan-European intergovernmental network that promotes collaborative R&D, and the European Union (EU) funding program Horizon 2020.\u00a0The EUREKA\u00a0Eurostars\u00a0grant is a highly competitive funding program for SMEs in Europe\u00a0with\u00a0multiple\u00a0SMEs across Europe vying for limited funding opportunities.<\/p>\n\n\n\n
Nemaura\u2019s\u00a0MAP technology is one that is expected to be available at very low cost once the commercial manufacture process has been\u00a0developed and\u00a0has the potential tobe adopted with a large range of vaccines and therapeutics.\u00a0<\/p>\n\n\n\n
Dr Chowdhury, CEO of\u00a0Nemaura\u00a0said: \u201cWe are delighted to have been awarded this highly competitive grant which we believe is a huge endorsement of both the innovative nature of our platform technology as well as the massive potential for future vaccine and drug delivery.\u201d<\/p>\n\n\n\n
Business Development enquiries:\u00a0<\/strong>\u00a0
bd@nemaura.co.uk<\/a><\/p>\n\n\n\n